Azithromycin has an unusually long tissue half-life of approximately 68 hours, allowing once-daily dosing and 3–5 day treatment courses. The pharmacokinetic explanation for this is:

• A High protein binding to albumin prolonging plasma residence time
• B Extensive sequestration in lysosomes (lysosomal trapping) due to its basic dibasic amine groups, resulting in an enormous volume of distribution (~31 L/kg) with slow release from tissues ✓
• C Inhibition of CYP3A4 preventing its own metabolism — autoinhibition extending half-life
• D Active tubular secretion recycling the drug repeatedly through an enterohepatic circulation

Explanation

Azithromycin has an extraordinary volume of distribution (~31 L/kg), one of the largest among clinical antibiotics. This is because azithromycin is a dibasic amine — it becomes ionized and trapped in acidic lysosomes of cells (lysosomal trapping or ion-trapping), concentrating in macrophages, phagocytes, and other cells to tissue/plasma ratios of 100–500:1. Drug slowly leaches back from tissues into plasma over days, maintaining therapeutic tissue concentrations long after plasma levels fall. This explains the post-antibiotic effect and short 3-day treatment courses. Azithromycin does not significantly inhibit CYP3A4 (unlike clarithromycin, which does).

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.